amiodarone / Generic mfg. - LARVOL DELTA

Implantable cardioverter-defibrillator therapy compared to amiodarone in Chagas cardiomyopathy: a systematic review and meta-analysis (ESC-WCC 2025) - "In patients with ChCM, ICD therapy significantly reduces the risk of SCD compared to amiodarone alone. However, this benefit does not appear to translate into reductions in all-cause mortality or heart failure-related mortality, underscoring the critical role of GDMT as the cornerstone of care. Further studies are needed to better evaluate its impact on broader clinical outcomes."

Retrospective data • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

Survival impact of amiodarone therapy in heart failure: insights from the Icelandic Heart Failure registry (ESC-WCC 2025) - "In this nationwide registry analysis, amiodarone treatment was not associated with survival benefit in either HFrEF or HFpEF patients, despite differences in baseline clinical characteristics. If a true mortality difference exists, the effect size is likely so small that a substantially larger sample would be required to detect it. These findings highlight the need for more personalized approaches to antiarrhythmic therapy in HF and warrant further investigation into alternative strategies for specific HF phenotypes."

Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension

In-silico insights into the role of patient-specific fibrosis in personalised therapy selection for atrial fibrillation (ESC-WCC 2025) - "Three AAD (vernakalant, amiodarone [acute, chronic], and flecainide) were virtually administered via ionic modulation in CARPentry software. This work highlights the added value of fibrosis-driven personalisation in therapeutic decision-making. It shows how incorporating patient-specific fibrosis more closely aligns success rates with clinical guidelines, offering a framework for personalised treatment."

Clinical • Atrial Fibrillation • Cardiovascular

Percutaneous left stellate ganglion block for acute supraventricular arrhythmias management: insights from a single-center experience (ESC-WCC 2025) - "Despite ongoing treatment with beta-blockers and amiodarone, SVAs had a mean ventricular cycle of 442 ± 61 ms... Our preliminary data suggest that PLSGB usage, due to its easy feasibility and rapid effect, may be effective in the acute management of drug refractory SVAs either by facilitating spontaneous or electrical CV and/or by reducing ventricular response."

Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Clinical profile and management of Wolf-Parkinson White syndrome and asymptomatic pre-excitation carriers in Africa: A multicenter pan African registry from 17 countries (ESC-WCC 2025) - "Approximately 30% of patients in Africa, except for the southern region, received intravenous amiodarone as the first-choice drug for orthodromic AVRT while adenosine was the drug of choice in the Southern region...Countries in Northern and Southern Africa are more advanced than other African countries in terms of modern management strategy. Additional government investments are necessary to enhance diagnostic likelihood and curative treatments as well as to reduce the gap between different regions in Africa."

Clinical • Atrial Fibrillation • Cardiovascular

Early rhythm control in patients with acute decompensated heart failure (ESC-WCC 2025) - "Rhythm control therapy was defined as cardioversion, use of antiarrhythmic drugs (amiodarone, dronedarone, flecainide, or propafenone) or AF ablation. These hypothesis-generating results support the evaluation of early rhythm control for outcome reduction in patients with AHF and AF."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Engineered pluripotent stem cell-derived cardiomyocytes prevent serious engraftment-related arrhythmia in nonhuman primates (ESC-WCC 2025) - "Sham transplant (n=1) was also performed, and all animals were treated with standard immunosuppression (cyclosporine/abatacept/methylprednisolone) and anti-arrhythmic (metoprolol/amiodarone) therapy to prevent xenograft rejection and arrhythmic death, respectively... Genetically-edited PSC-CMs without pacemaker-like activity engraft yet significantly reduce arrythmia burden and prevent serious engraftment-related arrhythmia in infarcted nonhuman primates. This study supports automaticity of donor cardiomyocytes as a central mechanism of engraftment arrythmia. Transplantation of "quiescent-yet-excitable" cardiomyocytes to prevent or reduce engraftment arrythmia warrants further investigation, specifically to ensure that efficacy is not adversely affected."

Cardiomyopathy • Cardiovascular • Myocardial Infarction • Reperfusion Injury • Ventricular Tachycardia • ACACA • CACNA1H • SLC8A1

Heart rate control in heart failure: insights from nationwide multicenter registry HEROES. (ESC-WCC 2025) - "Baseline use of beta-adrenolytics was 80% (increasing to 95% at discharge) and ivabradine was used in 4% (increase to 5%), amiodarone in 11% and digitalis in 8.5%. HR at presentation is weakly but significantly related with total 16-months mortality with optimal cutoff >82bpm for entire cohort and sinus rhythm pts, and with >73bpm for hospitalized pts. Elevated heart rate was a remarkable predictor of mortality in the subset of patients with preserved ejection fraction."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Salvage catheter ablation for life-threatening refractory ventricular arrhythmias during extracorporeal support after anterior myocardial infarction (ESC-WCC 2025) - "Despite LAD artery revascularization and high dose intravenous amiodarone and lidocaine, all patients continued to exhibit PVC-triggered PMVT/VF (Figure)... Catheter ablation of drug-refractory PMVT/VF following anterior MI in patients requiring ECPR can be undertaken safely and may result in procedural success (acute arrhythmia termination, discontinuance of ECPR, and ultimately hospital discharge) in approximately 50% of cases. However, early procedure related mortality is high, emphasizing the need to improve patient selection criteria. Future research should focus on determining predictors of survival in this critically ill population."

Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Ventricular Tachycardia

Rate vs. rhythm control in patients with transthyretin amyloid cardiomyopathy and atrial fibrillation (ESC-WCC 2025) - "In the rhythm control group 18 (48.6%) were on amiodarone, 4 (10.8%) had a pulmonary vein isolation, 25 (67.6%) had at least one electrical cardioversion and 27 (73%) were on tafamidis. In the rate control group 42 (51.8%) were on beta blockers, 8 (9.9%) on calcium channel blockers, 1 (1.2%) on digoxin and 53 (65.4%) on tafamidis...Cardiovascular death, NYHA-worsening and the cumulative endpoint, albeit trending lower in the rhythm control group, showed no statistically significant differences. Heart failure-related hospitalisations were lower in the rate control group but did not meet statistical significance."

Clinical • Atrial Fibrillation • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Prognostic comparison between implantable cardioverter-defibrillator and amiodarone in cancer patients (ESC-WCC 2025) - "Conversely, among patients with cancer stage: regional or distant, the ICD group had significantly reduced risk of all-cause death than the Amiodaron group, and ICD was an independent prognostic factor. Conclusion In cancer patients, ICD may improve long-term prognosis compared to amiodarone, especially in patients with advanced cancer stages."

Clinical • Cardiovascular

Timing of first-time catheter ablation in patients with atrial fibrillation and heart failure - Insights from a Danish nationwide cohort (ESC-WCC 2025) - "AF recurrence was defined as first occurrence of either AF hospitalization, new prescription of anti-arrhythmic drugs (class 1C anti-arrhythmic drugs, dronedarone or amiodarone), electrical cardio-version, or AF re-ablation, with death as competing risk and censoring for emigration. The timing of ablation for patients with AF and HF may impact catheter ablation efficacy. Longer DAT was associated with increased risk of AF recurrence, but there was no significant increased risk of MACE."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Nationwide insights into QTc prolongation, demographic disparities, and cardiovascular risk factors in Denmark (ESC-WCC 2025) - "They were also more frequently on cardiac medications (e.g., acetylsalicylic acid and betablockers). Of note, only 0.9% of the prolonged QTc group were on amiodarone...Patients with prolonged QTc were generally older, predominantly male, had more comorbidities, lower socioeconomic status, and more frequently ECG abnormalities compared to those with normal QTc. The observed trends of higher median QTc in males and increasing QTc with advancing age emphasize the need for age- and gender-specific reference ranges."

Clinical • Atrial Fibrillation • Cardiovascular • Hypertension • Ventricular Tachycardia

A multicenter analysis of atrial fibrillation burden reduction with antiarrhythmic drugs in patients with cardiac implantable electronic devices (ESC-WCC 2025) - "A significant reduction in AF burden was seen at both timepoints in patient subgroups taking amiodarone (pre 6.4% [IQR 1-36%], first post 0.1% [IQR 0-1.5%], final 0.1% [IQR 0-1.1%]), non-amiodarone AADs (pre 5% [IQR 1.5-21.5%], first post 1% [IQR 0-5%], final 0.1% [IQR 0-2.9%]), and high baseline AF burden (≥90%) (pre 100% [IQR 99.9-100%], first post 0.1% [IQR 0-71.1%], final 0.1% [IQR 0-59.7%]) and low baseline AF burden (≤20%) (pre 2.2% [IQR 0.8-6.1%], first post 0.1% [IQR 0-1%], final 0.1% [IQR 0-0.9%]) (p-value for all <0.05)...Conclusions There was a median 97.4% [IQR 35.7-100%] reduction in AF burden following AAD initiation in CIED patients through the final interrogation. Results are consistent in subgroups based on AAD type and baseline AF burden."

Clinical • Atrial Fibrillation • Cardiovascular

Hypo- and hyperthyroidism in patients with new-onset atrial fibrillation: a nationwide study (ESC-WCC 2025) - "We excluded those with missing laboratory data, radioactive iodine or amiodarone therapy before the cohort entry...These figures seem to be higher compared to the available literature. Patients with hyperthyroidism in the history had the poorest survival."

Clinical • Atrial Fibrillation • Cardiovascular

Use of antiarrhythmic drugs in elderly patients with nonvalvular atrial fibrillation: analysis of the italian multicenter START registry. (ESC-WCC 2025) - "However, these associations were not confirmed on multivariate analysis where neither class 1c AADs nor amiodarone were significantly associated with increased mortality (HR: 0.643, 95% CI: 0.327-1.264, p=0. 200 for AAD class 1c and HR: 1.118, 95% CI 0.835-1.496, p=0.453 for amiodarone) and cardiovascular events (HR: 0.703 95% CI: 0.390-1.265, p=0.239 for AAD class 1c and HR: 1.027, 95% CI: 0.774-1.361, p=0.856 for amiodarone).ConclusionsIn elderly patients with AF, the use of class 1c AADs and amiodarone is not associated with a reduction in the risk of mortality or cardiovascular events, therefore long-term treatment with these drugs should be carefully evaluated in the individual patient weighing up the risks and benefits."

Clinical • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease

Impact of rhythm control in wild-type transthyretin cardiac amyloidosis and atrial fibrillation: a retrospective analysis (ESC-WCC 2025) - "A subgroup analysis was performed to compare AF/AFL patients receiving rhythm control (RC) therapy (including electrical cardioversion (eCV), pulmonary vein isolation (PVI), and amiodarone) to those without RC... AF/AFL is common in ATTRwt-CM, and RC strategies showed poor long-term effectiveness. Rhythm control did not impact NYHA class, laboratory biomarkers, or echocardiographic parameters. Future prospective studies are needed to optimize AF/AFL management in ATTRwt-CM, focusing on the most effective RC strategies."

Retrospective data • Atrial Fibrillation • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure

Amiodarone-induced vasculitis ended by limb loss in a patient with rheumatic heart disease (ESC-WCC 2025) - "Implementation of the ESC Guidelines"

Clinical • Cardiovascular • Heart Failure

Atypical Presentation of Systemic Amyloid Light Chain (AL) Amyloidosis. (PubMed, Cureus) - "Atrial fibrillation was noted on ECG and was treated with both rate- and rhythm-controlled amiodarone...However, this is neither supported nor refuted as the gold standard by the available literature. The patient was transferred to a higher level of care at a center specifically focused on the treatment of amyloidosis to receive the current gold standard of treatment, which was unavailable at our facility due to a lack of these specialized medications, as well as a provider comfortable with the use of these treatments."

Journal • Amyloidosis • Atrial Fibrillation • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Fatigue • Heart Failure • Respiratory Diseases

Fetal Supraventricular Tachycardia: What Do We Know up to This Day? (PubMed, J Pers Med) - "The review, also, focuses on pharmacologic management via transplacental therapy, discussing the safety and efficacy of the key agents including digoxin, flecainide, and sotalol, under different clinical scenarios, such as hydropic fetus and renal impairment...The limitations of current evidence, largely based on small case studies and retrospective analyses, underscore the need for larger, prospective multicenter observational studies and randomized control trials to establish standardized protocols for fetal tachyarrhythmia management. Overall, this review advocates for a personalized, multidisciplinary approach, emphasizing early fetal tachyarrhythmias diagnosis, tailored treatment regimens that balances efficacy with safety, and rigorous monitoring to optimize outcomes for both the fetus and the mother."

Journal • Review • Cardiovascular • Renal Disease • Ventricular Tachycardia

Chronic Obstructive Pulmonary Disease is Associated with Higher Recurrence Rates of Atrial Fibrillation Following Catheter Ablation. (PubMed, Indian Pacing Electrophysiol J) - "Patients with AF and COPD were more likely than patients with AF but without COPD to experience AF recurrence following catheter ablation. Predictors of AF recurrence included decreased use of loop diuretics and amiodarone. Our study demonstrates that while ablation in patients with COPD is safe, ablation in patients with COPD is associated with higher AF recurrence rates."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Management and Outcomes Following Coronary Artery Bypass Graft and Liver Transplant (ACG 2025) - "Postoperative complications include atrial fibrillation managed with amiodarone weaned off at 3 months, severe diarrhea necessitating immunosuppressant adjustments, hyperkalemia with acute kidney injury, and prolonged debility requiring inpatient rehabilitation...Early postoperative complications commonly include cardiac arrhythmias and transplant-specific issues. Long-term outcomes depend on comprehensive management of cardiovascular, metabolic, and transplant-related risks."

Acute Kidney Injury • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Nephrology • Solid Tumor • Thrombosis • Transplantation

Missed in Translation: Preventable Hepatotoxicity From Amiodarone Overdose in a LEP Patient (ACG 2025) - "Concomitant atorvastatin likely compounded hepatic stress. This case underscores the clinical consequences of unaddressed language barriers and highlights the need for professional interpreter use and multilingual medication education in patients prescribed high-risk therapies.This case illustrates how communication failure in LEP patients can lead to life-threatening drug toxicity. Ensuring access to certified interpreters, visual medication guides, and structured patient education is essential to reducing preventable harm and improving medication safety in diverse patient populations.Figure: LFT Trend Following Amiodarone Overdose Due to Language-Related Medication Error"

Clinical • Cardiovascular • Fatigue • Hepatology • Infectious Disease • Influenza • Liver Failure • Respiratory Diseases

Sweet but Not Innocent: A Case of D-Mannose and Amiodarone-Induced Pancreatitis (ACG 2025) - "She took Eliquis and Rosuvastatin daily, unchanged for many years...4 months later, she presented with atrial fibrillation and RVR, unresponsive to diltiazem for which she required amiodarone...It is likely, use of amiodarone exacerbated her pancreatitis due to accumulation in the pancreas leading to synergy. This case highlights the importance of considering uncommon causes and underscores the need for a meticulous medication reconciliation.Figure: Axial view of CT abdomen/pelvis showing acute interstitial edematous pancreatitis, a mildly hydropic gallbladder, small bilateral pleural effusions and sigmoid colon diverticulosis without diverticulitis and a stable renal cystFigure: Coronal view of CT abdomen/pelvis showing acute interstitial edematous pancreatitis"

Clinical • Addiction (Opioid and Alcohol) • Atrial Fibrillation • Cardiovascular • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertriglyceridemia • Infectious Disease • Nephrology • Pancreatitis • Respiratory Diseases • Thrombosis

A Case Report (ACG 2025) - "Twelve hours later, liver function tests (LFTs) showed severe elevations in ALT, AST, and bilirubin levels in hepatocellular pattern despite prior normal levels as trends shown in Table 1 Amiodarone was immediately discontinued and metoprolol succinate was used for rate control. Additionally, recovery achieved through discontinuing amiodarone further reinforced the suspicion of drug-induced injury. Figure: Table 1"

Case report • Clinical • Atrial Fibrillation • Autoimmune Hepatitis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hepatology • Hypotension • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders